Loading... Please wait...
Sort by:
  • Benchmarking Key Account Management Capabilities (2019)
    Learn More Benchmarking Key Account Management Capabilities (2019)
    What factors determine a Key Account Manager (KAM) team's size and structure? At what stage in a product's lifecycle are KAMs assigned and how many brands should a typical KAM support? What personal attributes and...
  • Biomarkers and Companion diagnostics: Payer Insights
    Learn More Biomarkers and Companion diagnostics: Payer Insights
    What do you need to do to get payer support for companion diagnostics and biomarkers? The investment decisions made by the biggest players in core disease areas drive market trends—so it's crucial to understand...
  • The Future of Disease Interception
    Learn More The Future of Disease Interception
    What does pharma need to do to develop this radical health model of the future? Disease interception is a novel healthcare model that identifies, treats and sometimes cures disease before it is fully manifested. There...
  • The Future of Key Account Management in Pharma
    Learn More The Future of Key Account Management in Pharma
    Are you ready for fundamental disruption to key account management practice? While the Key Account Management (KAM) role will continue to prioritise the development of long-term, sustainable partnerships between...
  • Trends in Investment by Big Pharma
    Learn More Trends in Investment by Big Pharma
    What direction are big pharma investments taking? The investment decisions made by the biggest players in core disease areas drive market trends—so it's crucial to understand where the big money is going and why...
  • Biosimilars: The Importance of Real-World Evidence (2019)
    Learn More Biosimilars: The Importance of Real-World Evidence (2019)
    Are you generating the right RWE to influence the right stakeholders? As the biosimilar sector continues to evolve and experience of their use deepens, what role should real-world evidence (RWE) now take in stakeholder...
  • Real-World Data Capabilities: Benchmarking Pharma Companies (2019)
    Learn More Real-World Data Capabilities: Benchmarking Pharma Companies (2019)
    Are you fully and efficiently exploiting real-world data across your business? The impact of real-world data (RWD) is growing but few companies are fully exploiting its potential across all clinical and commercial areas...
  • Financing High-Cost Therapies through Reinsurance
    Learn More Financing High-Cost Therapies through Reinsurance
    Could reinsurance allay health insurers' fear about high cell and gene therapy costs? With the prospect of many cell and gene therapies coming to market in the medium term, often with record breaking list prices and...
  • Biosimilars: European Payer Insights (2019)
    Learn More Biosimilars: European Payer Insights (2019)
    As the European biosimilars market surges, what do payers see as the next steps? The approval in 2018 of biosimilar versions of adalimumab (Abbvie's Humira) and trastuzumab (Roche's Herceptin) is a major boost to the...
  • Paying for Gene Therapy: Payer Insights
    Learn More Paying for Gene Therapy: Payer Insights
    Payers caution pharma to think hard about price if they want support for their gene therapies The message from payers is stark: developers who present gene therapies with limited clinical data, eye wateringly high...
  • Orphan Drugs: Drivers of Market Growth (2019)
    Learn More Orphan Drugs: Drivers of Market Growth (2019)
    Orphan drugs: Building your profits or draining your resources? Substantial growth prospects in orphan drugs (more than double the overall pharma market) have enticed many pharma companies to enter the fray. But all...
  • Trends in KOL Experience Management
    Learn More Trends in KOL Experience Management
    How well does your MSL KOL engagement activity compare to competitors? What tools are being used today to measure engagement with KOLs? How often are KOLs surveyed regarding satisfaction levels? Which metrics are...
  • KAM Metrics: Measuring Success (2019)
    Learn More KAM Metrics: Measuring Success (2019)
    Secure a successful future for your KAM teams by proving their true value KAM teams are still evolving but they're also concerned about their future. They need appropriate measures to demonstrate their true value...
  • Indication-level Pricing: Payer Insights
    Learn More Indication-level Pricing: Payer Insights
    Can pharma persuade payers of the benefits of indication-level pricing? Advocates argue that indication-level pricing can bring new products on stream and results in wider patient access to new therapies. That's a good...
  • MSL Teams: Field Force size and structure (2019)
    Learn More MSL Teams: Field Force size and structure (2019)
    What factors determine the optimum MSL field-based team size and structure? How many brands should MSL field-based teams represent and what constitutes an acceptable territory? What educational background and...
  • Real World Data and Evidence: Payer Insights
    Learn More Real World Data and Evidence: Payer Insights
    Payers have great expectations for real world data. Is pharma meeting them? It's sink or swim time. Advancements in drug data collection methodologies and deeper understanding of what can be achieved has finally opened...

customer.service@firstwordpharma.com

All Contents Copyright © 2019 Doctor's Guide Publishing Limited All Rights Reserved